Medical College of Wisconsin: Multiple Myeloma trials

The registry lists 19 Multiple Myeloma studies with Medical College of Wisconsin as lead sponsor. 7 are open to participants now and 5 have results posted.

Phase 1 4Phase 2 11No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple MyelomaRecruitingNCT07236502Not applicable
• FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple MyelomaNot yet recruitingNCT07221032Phase 1
• Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07093554Phase 1
• BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)Not yet recruitingNCT07009899Phase 2
• Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory MyelomaRecruitingNCT05976555Phase 1
• Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyRecruitingNCT04240054Phase 2
• Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruitingNCT03375619
• Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT05117008Phase 2Results posted
• Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedNCT05032820Phase 2Results posted
• Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationCompletedNCT03159702Phase 2Results posted
• Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous TransplantationCompletedNCT02669615Phase 2Results posted
• Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT RecipientsCompletedNCT02420223Phase 2Results posted
• Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
• Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT04835129Phase 2
• INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple MyelomaWithdrawnNCT04355039Phase 1
• Effect of Sleep Quality on Hematopoietic Cell Transplant Patient OutcomesTerminatedNCT04271930Not applicable
• Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03200626
• Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow TransplantationStatus unknownNCT00036712Phase 2
• Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersStatus unknownNCT00003163Phase 2